These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 38146118)

  • 41. Tissue injury and leukocyte changes in post-acute sequelae of SARS-CoV-2: review of 2833 post-acute patient outcomes per immune dysregulation and microbial translocation in long COVID.
    Islam MS; Wang Z; Abdel-Mohsen M; Chen X; Montaner LJ
    J Leukoc Biol; 2023 Mar; 113(3):236-254. PubMed ID: 36807444
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Humoral immunity to an endemic coronavirus is associated with postacute sequelae of COVID-19 in individuals with rheumatic diseases.
    Herman JD; Atyeo C; Zur Y; Cook CE; Patel NJ; Vanni KM; Kowalski EN; Qian G; Srivatsan S; Shadick NA; Rao DA; Kellman B; Mann CJ; Lauffenburger D; Wallace ZS; Sparks JA; Alter G
    Sci Transl Med; 2023 Sep; 15(712):eadf6598. PubMed ID: 37672567
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Persistence of SARS CoV-2 S1 Protein in CD16+ Monocytes in Post-Acute Sequelae of COVID-19 (PASC) up to 15 Months Post-Infection.
    Patterson BK; Francisco EB; Yogendra R; Long E; Pise A; Rodrigues H; Hall E; Herrera M; Parikh P; Guevara-Coto J; Triche TJ; Scott P; Hekmati S; Maglinte D; Chang X; Mora-Rodríguez RA; Mora J
    Front Immunol; 2021; 12():746021. PubMed ID: 35082777
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Association of SARS-CoV-2 Seropositivity With Myalgic Encephalomyelitis and/or Chronic Fatigue Syndrome Among Children and Adolescents in Germany.
    Sorg AL; Becht S; Jank M; Armann J; von Both U; Hufnagel M; Lander F; Liese JG; Niehues T; Verjans E; Wetzke M; Stojanov S; Behrends U; Drosten C; Schroten H; von Kries R
    JAMA Netw Open; 2022 Sep; 5(9):e2233454. PubMed ID: 36166227
    [TBL] [Abstract][Full Text] [Related]  

  • 45. SARS-CoV-2 reservoir in post-acute sequelae of COVID-19 (PASC).
    Proal AD; VanElzakker MB; Aleman S; Bach K; Boribong BP; Buggert M; Cherry S; Chertow DS; Davies HE; Dupont CL; Deeks SG; Eimer W; Ely EW; Fasano A; Freire M; Geng LN; Griffin DE; Henrich TJ; Iwasaki A; Izquierdo-Garcia D; Locci M; Mehandru S; Painter MM; Peluso MJ; Pretorius E; Price DA; Putrino D; Scheuermann RH; Tan GS; Tanzi RE; VanBrocklin HF; Yonker LM; Wherry EJ
    Nat Immunol; 2023 Oct; 24(10):1616-1627. PubMed ID: 37667052
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prevalence and determinants of post-acute sequelae of COVID-19 in Liberia.
    Gwaikolo C; Sackie-Wapoe Y; Badio M; Glidden DV; Lindan C; Martin J
    Int J Epidemiol; 2024 Feb; 53(1):. PubMed ID: 38052015
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Genetic risk factors for severe and fatigue dominant long COVID and commonalities with ME/CFS identified by combinatorial analysis.
    Taylor K; Pearson M; Das S; Sardell J; Chocian K; Gardner S
    J Transl Med; 2023 Nov; 21(1):775. PubMed ID: 37915075
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long COVID or Post-acute Sequelae of COVID-19 (PASC): An Overview of Biological Factors That May Contribute to Persistent Symptoms.
    Proal AD; VanElzakker MB
    Front Microbiol; 2021; 12():698169. PubMed ID: 34248921
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin.
    Pretorius E; Vlok M; Venter C; Bezuidenhout JA; Laubscher GJ; Steenkamp J; Kell DB
    Cardiovasc Diabetol; 2021 Aug; 20(1):172. PubMed ID: 34425843
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pediatric Post-Acute Sequelae of SARS-CoV-2 Infection.
    Jason LA; Johnson M; Torres C
    Fatigue; 2023; 11(2-4):55-65. PubMed ID: 38044956
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Use of Cardiopulmonary Stress Testing for Patients With Unexplained Dyspnea Post-Coronavirus Disease.
    Mancini DM; Brunjes DL; Lala A; Trivieri MG; Contreras JP; Natelson BH
    JACC Heart Fail; 2021 Dec; 9(12):927-937. PubMed ID: 34857177
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Analysis of post COVID-19 condition and its overlap with myalgic encephalomyelitis/chronic fatigue syndrome.
    Sukocheva OA; Maksoud R; Beeraka NM; Madhunapantula SV; Sinelnikov M; Nikolenko VN; Neganova ME; Klochkov SG; Amjad Kamal M; Staines DR; Marshall-Gradisnik S
    J Adv Res; 2022 Sep; 40():179-196. PubMed ID: 36100326
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Single-cell RNA sequencing reveals characteristics of myeloid cells in post-acute sequelae of SARS-CoV-2 patients with persistent respiratory symptoms.
    Yoon H; Dean LS; Jiyarom B; Khadka VS; Deng Y; Nerurkar VR; Chow DC; Shikuma CM; Devendra G; Koh Y; Park J
    Front Immunol; 2023; 14():1268510. PubMed ID: 38259488
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Symptom Burden and Immune Dynamics 6 to 18 Months Following Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2): A Case-control Study.
    Fjelltveit EB; Blomberg B; Kuwelker K; Zhou F; Onyango TB; Brokstad KA; Elyanow R; Kaplan IM; Tøndel C; Mohn KGI; Özgümüş T; Cox RJ; Langeland N;
    Clin Infect Dis; 2023 Feb; 76(3):e60-e70. PubMed ID: 35959897
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Persistent circulation of soluble and extracellular vesicle-linked Spike protein in individuals with postacute sequelae of COVID-19.
    Craddock V; Mahajan A; Spikes L; Krishnamachary B; Ram AK; Kumar A; Chen L; Chalise P; Dhillon NK
    J Med Virol; 2023 Feb; 95(2):e28568. PubMed ID: 36756925
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Low-dose naltrexone use for the management of post-acute sequelae of COVID-19.
    Bonilla H; Tian L; Marconi VC; Shafer R; McComsey GA; Miglis M; Yang P; Bonilla A; Eggert L; Geng LN
    Int Immunopharmacol; 2023 Nov; 124(Pt B):110966. PubMed ID: 37804660
    [TBL] [Abstract][Full Text] [Related]  

  • 57. SARS-CoV-2 specific T-cell immunity in COVID-19 convalescent patients and unexposed controls measured by ex vivo ELISpot assay.
    Cassaniti I; Percivalle E; Bergami F; Piralla A; Comolli G; Bruno R; Vecchia M; Sambo M; Colaneri M; Zuccaro V; Benazzo M; Robotti C; Calastri A; Maiorano E; Ferrari A; Cambiè G; Baldanti F
    Clin Microbiol Infect; 2021 Jul; 27(7):1029-1034. PubMed ID: 33813122
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Potent SARS-CoV-2-Specific T Cell Immunity and Low Anaphylatoxin Levels Correlate With Mild Disease Progression in COVID-19 Patients.
    Lafon E; Diem G; Witting C; Zaderer V; Bellmann-Weiler RM; Reindl M; Bauer A; Griesmacher A; Fux V; Hoermann G; Miller C; Zabernigg A; Wöll E; Wilflingseder D; Lass-Flörl C; Posch W
    Front Immunol; 2021; 12():684014. PubMed ID: 34194438
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prevalence of symptoms, comorbidities, fibrin amyloid microclots and platelet pathology in individuals with Long COVID/Post-Acute Sequelae of COVID-19 (PASC).
    Pretorius E; Venter C; Laubscher GJ; Kotze MJ; Oladejo SO; Watson LR; Rajaratnam K; Watson BW; Kell DB
    Cardiovasc Diabetol; 2022 Aug; 21(1):148. PubMed ID: 35933347
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Post-acute symptoms 3-15 months after COVID-19 among unvaccinated and vaccinated individuals with a breakthrough infection.
    Brunvoll SH; Nygaard AB; Fagerland MW; Holland P; Ellingjord-Dale M; Dahl JA; Søraas A
    Int J Infect Dis; 2023 Jan; 126():10-13. PubMed ID: 36375693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.